Lineage Cell Therapeutics Inc (LCTX)
Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cell replacement therapies for serious medical conditions in the United States and internationally. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelium cell therapy being studied in a Phase 2a trial for age-related macular degeneration, and OPC1, an allogeneic oligodendrocyte progenitor cell therapy in a Phase 1/2a multicenter trial for cervical spinal cord injury. The company is also advancing preclinical programs such as ReSonance (ANP1) for sensorineural hearing loss and PNC1 for vision loss linked to photoreceptor damage or dysfunction. Additional development work includes RND1, a hypoimmune induced pluripotent stem cell line, as well as research activities in ILT1 and LCT-CON across areas including retinal disease, neurological disease, ophthalmology, metabolic disorders, and oncology. Lineage Cell Therapeutics is headquartered in Carlsbad, California, and was formerly known as BioTime, Inc.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-LCTX
|
$1.14
|
11.1% Upside
|
Fair
|
$5.50
|
434.0% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
4.3x
|
19.9x
|
260.5 M
|
210.8 M
|
0.9%
|
75.5%
|
-7.3
|
75.6%
|
